Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026764 (
multiple myeloma
)
36,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The combination of
polycythemia
and
plasma cell myeloma
occurring concurrently is very rare and few cases have been reported in the literature. Further, the vast majority of these cases are cases of polycythemia vera and
myeloma
. Here, we present a case of
polycythemia
of undetermined etiology and
myeloma
. The patient is a 48-year-old Caucasian male who was originally diagnosed with
polycythemia
of undetermined etiology. Twelve years later, when a bone marrow biopsy was performed in an attempt to determine the etiology of the
polycythemia
, findings diagnostic of
plasma cell myeloma
were discovered. Subsequent serum studies were also consistent with a
plasma cell neoplasm
, while evaluation for end-organ damage was negative. A battery of genetic and biochemical tests ruled out various congenital polycythemias, leading to a final diagnosis of
polycythemia
of undetermined etiology and smouldering
plasma cell myeloma
. This case highlights that while being unusual,
polycythemia
and
plasma cell myeloma
can occur concurrently, and, in this report, we discuss both entities and potential mechanisms of the pathophysiology of the concurrent presentation.
...
PMID:Concurrent Polycythemia of Undetermined Etiology and Smouldering Plasma Cell Myeloma. 3030 75
Hematological malignancies can cause bone lesions, of which the most common are the punched-out foci of osteolysis seen in
multiple myeloma
. However, osteosclerotic lesions are more common in myeloproliferative disorders. We report the unusual case of a patient with myeloproliferative syndrome in whom the development of osteolytic lesions revealed transformation to acute leukemia. In 2007, this 82-year-old man with essential thrombocythemia since 1994 developed primary
polycythemia
with the JAK2 mutation V617F. In July 2017, he was evaluated for an osteolytic lesion in the right humerus with incipient fracturing. Bone marrow smear results provided only limited information, due to the myelofibrosis, showing 7% of blast cells with no plasmacytosis. No solid malignancies were identified by imaging studies. Examination of a right humeral biopsy specimen taken during internal fixation showed myeloproliferative syndrome with osteosclerosis and grade-3 myelofibrosis, as well as a malignant proliferation of large cells carrying the leukocyte cluster of differentiation antigens CD45, CD 43, CD4, and CD34. The diagnosis was transformation of the myeloproliferative syndrome to acute myeloid leukemia. The development of an osteolytic lesion during the course of myeloproliferative syndrome is an exceedingly rare event that should suggest acute leukemic transformation.
...
PMID:Singular case of osteolytic lesions revealing transformation of myeloproliferative syndrome to acute leukemia. 3047 21
<< Previous
1
2
3
